Glioblastoma Clinical Trial Delivers Promising Results

There's one company on our radar that is targeting the most aggressive type of brain cancer. [Unsubscribe]( | [View In Browser]( | [Report Spam]( [Investr Logo - Click Here](  ⏰ [HURRY] This Tiny Tech Stock Set To Pay Out Big in 2021 Our insider research suggests this tech stock could generate very hefty profits for fast-moving investors for the next 3, 6 months & beyond. It’s a simple buy & hold play, get the full scoop here. [Get This Free Bonus Here] {EMAIL} [Get the cheatsheet now!]( (by clicking the link below you are subscribing to the Stock Fellas newsletter and may receive up to 2 additional free Bonus subscriptions. Unsubscribe. anytime. [Privacy]( [Brain Cancer Patient from Phase 1]( [Clinical Trial Remains Cancer Free]( The NASDAQ stock exchange is abundant with emerging growth biotech stocks, but there is one company on our radar that is targeting the most aggressive type of brain cancer.  [They IPO'd at $4 per share]( and expect to initiate their Phase II clinical trial during Q2 of 2021.  As of November 2020, a patient from their Phase 1 clinical trial for the treatment of glioblastoma multiforme ("GBM"), remains cancer free.  GBM is the most aggressive type of brain cancer that led to the death of Senator Ted Kennedy, Senator John McCain, and President Joe Biden's son. As of today, there are no effective therapies approved to treat this disease.  We've put together a detailed report on why we believe it offers investors a unique opportunity in the biotech space.  [Click here to read the full release from the featured company and learn more about its capabilities.](  [Click here](  The image on the left is pre-treatment and the one on the right is 6-months post-treatment.        [Unsubscribe]( | [Report Spam]( If you are you having trouble receiving your EBA subscription, you can ensure its arrival in your mailbox by whitelisting EBA and eba@earlybirdalert.co.  This message was sent to {EMAIL} on Thursday July 15, 2021.  EBA and 8020 Publishing (collectively, the “Company” or “we” used herein) bears no responsibility or control over the content of the advertisement and/or the product or service offered.  This email is a paid advertisement. It is for a product or service that is not offered, recommended or endorsed by EBA and neither the company nor its affiliates bear responsibility or control over the content of the advertisement and the product or service offered. There is a very high degree of risk involved in trading. Past results are not indicative of future returns. EBA, all individuals and companies affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as advice. Information for any trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. By reading, downloading or otherwise consuming this content your information may be shared with our educational partners. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of EBA may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies. To opt out, either [REPLY](mailto:?subject=Unsubscribe%20Request%20-%20{EMAIL}&body=Please%20unsubscribe%20me%2C%20my%20subscription%20email%20is%3A%20{EMAIL}) to this message or click on the link in the footer of this email (allow up to 72 hours for the system to fully process your request).  Your subscriber Id is: cfe849c006f209a6431c6cc167a3577c Proudly brought to you by: EBA of 3rd Fl, N&S Tower, 4 Selsdon Way, London, E14 9GL, UK In order to unsubscribe from this mailing list, please click [here](